From extrapolation to evidence: BNT162b2 (Pfizer-BioNTech COVID-19 vaccine) safety and immunogenicity in adolescents with juvenile immune-mediated inflammatory disease. Journal Abstract - Guideline Central

From extrapolation to evidence: BNT162b2 (Pfizer-BioNTech COVID-19 vaccine) safety and immunogenicity in adolescents with juvenile immune-mediated inflammatory disease.

Published: 2026 Apr 18

Authors

,

Source

Pediatric research

Publication Type

Journal Article

Language

English

PubMed ID

41998335

You rely on Guideline Central for transparency

Guideline Central and select third party use “cookies” on this website to enhance the user experience.

This technology helps us gather statistical and analytical information to optimize the relevant content for you.

The user also has the option to opt-out which may have an effect on the browsing experience.